Patents by Inventor Liam Byrne

Liam Byrne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modulators of Rho-associated protein kinase
    Patent number: 11878020
    Abstract: This invention relates to novel compounds and pharmaceutical compositions comprising. Compounds of the invention useful as modulators of Rho-associated protein kinase (ROCK), for example ROCK1 and/or ROCK2 inhibitors. Methods of treatment employing the compounds are also contemplated by the present invention. The compounds of the invention are useful in treating ROCK mediated diseases.
    Type: Grant
    Filed: August 26, 2022
    Date of Patent: January 23, 2024
    Assignee: Redx Pharma PLC
    Inventors: Clifford D. Jones, Peter Bunyard, Gary Pitt, Liam Byrne, Thomas Pesnot, Nicolas E. S. Guisot
  • BIENZYMATIC BIOSENSOR FOR THE DETECTION OF LACTULOSE IN BLOOD
    Publication number: 20230108730
    Abstract: A method for determining the concentration of lactulose in a blood sample comprises the steps of converting lactulose in the blood sample into an entity including galactose, and converting the galactose into D-galacto-hexodialdose and hydrogen peroxide, which is detected. The detected quantity is processed to generate an output which is representative of the concentration of lactulose in the blood sample.
    Type: Application
    Filed: February 17, 2021
    Publication date: April 6, 2023
    Applicant: TRIVIUMVET DESIGNATED ACTIVITY COMPANY
    Inventors: Louise GRUBB, Stuart FITZGERALD, Liam BYRNE
  • MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE
    Publication number: 20230021916
    Abstract: This invention relates to novel compounds and pharmaceutical compositions comprising. Compounds of the invention useful as modulators of Rho-associated protein kinase (ROCK), for example ROCK1 and/or ROCK2 inhibitors. Methods of treatment employing the compounds are also contemplated by the present invention. The compounds of the invention are useful in treating ROCK mediated diseases.
    Type: Application
    Filed: August 26, 2022
    Publication date: January 26, 2023
    Inventors: Clifford D. Jones, Peter Bunyard, Gary Pitt, Liam Byrne, Thomas Pesnot, Nicolas E.S. Guisot
  • VETERINARY FORMULATIONS COMPRISING RAPAMYCIN AND METHODS OF USING THE SAME FOR TREATING ANIMAL DISEASE
    Publication number: 20220401421
    Abstract: The present disclosure provides veterinary formulations comprising rapamycin or rapalogs for administration to companion animals and methods of using the formulations to treat cardiac dysfunction, including hypertrophic cardiomyopathy, dilated cardiomyopathy, mitral valve disease, pressure-overload cardiac hypertrophy, cancer, effects of aging, inflammatory disease, and viral infection.
    Type: Application
    Filed: December 18, 2020
    Publication date: December 22, 2022
    Inventors: Tom BRENNAN, Louise GRUBB, Liam BYRNE, Stuart FITZGERALD
  • Modulators of Rho-associated protein kinase
    Patent number: 11497751
    Abstract: This invention relates to novel compounds and pharmaceutical compositions comprising the same. Compounds of the invention useful as modulators of Rho-associated protein kinase (ROCK), for example ROCK1 and/or ROCK2 inhibitors. Methods of treatment employing the compounds are also contemplated by the present invention. The compounds of the invention are useful in treating ROCK mediated diseases.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: November 15, 2022
    Assignee: Redx Pharma PLC
    Inventors: Clifford D. Jones, Peter Bunyard, Gary Pitt, Liam Byrne, Thomas Pesnot, Nicolas E. S. Guisot
  • Modulators of Rho-associated Protein Kinase
    Publication number: 20210038606
    Abstract: This invention relates to novel compounds and pharmaceutical compositions comprising the same. Compounds of the invention useful as modulators of Rho-associated protein kinase (ROCK), for example ROCK1 and/or ROCK2 inhibitors. Methods of treatment employing the compounds are also contemplated by the present invention. The compounds of the invention are useful in treating ROCK mediated diseases.
    Type: Application
    Filed: January 25, 2019
    Publication date: February 11, 2021
    Inventors: Clifford D. Jones, Peter Bunyard, Gary Pitt, Liam Byrne, Thomas Pesnot, Nicolas E.S. Guisot